Table 2.
MiRSNPs as biomarkers of chemotherapy response and survival.
| Gene | MirSNPs | Involved miRNAs | Cancer Types | Association with Variant Allele | References |
|---|---|---|---|---|---|
| SET8 | rs16917496 T > C | miR-502 | SCLC | Increased OS | [105] |
| NSCLC | Increased OS and reduced risk of death | [106] | |||
| CD133 | rs2240688 A > C | miR-135a/b | LC | Increased OS | [107] |
| KRT81 | rs3660 C > G | miR-17 | NSCLC | Increased time to recurrence | [108] |
| FAS | rs2234978 A > G | miR-651 | NSCLC | Reduced OS | [109] |
| FZD4 | rs713065 A > G | miR-204 | NSCLC | Increased OS | [109,110] |
| KRAS | rs61764370 T > G | let-7 | CRC | Poor response to cetuximab-irinotecan therapy and reduced OS/PFS | [111] |
| CRC | Resistance to anti-EGFR-based therapy | [112] | |||
| CRC | Improved OS/PFS | [113,114] | |||
| MDM4 | rs4245739 C > A | miR-191 | OC | Delayed progression and tumor related death | [115] |
| rs10900596 G > A | miR-409-3p a | OC | Better treatment response | [116] | |
| PDGFC | rs1425486 G > A | miR-425 | OC | Poor treatment response and reduced OS | [116] |
| KRAS | rs10771184 T > A | miR-544 | OC | Better treatment response and increased OS | [116] |
| SET8 | rs16917496 T > C | miR-502 | HCC | Increased OS | [117] |
| KRT81 | rs3660 C > G | miR-17 | HL | Increased risk of neurological toxicity | [118] |
| KRT81 | rs3660 C > G | miR-17 | MM | Increased OS | [119] |
| AP-2α | rs1045385 A > C | miR-200b, -200c, -429 | BC | Increased cisplatin sensitivity | [120] |
| CDON | rs3737336 T > C | miR-181c, -5007 a | PC | Recreased PFS | [121,122] |
| miR-196a-2 | rs11614913 C > T | NSCLC | Decreased risk of overall toxicity and increased OS/DFS | [123,124] | |
| miR-149 | rs2292832 T > C | NSCLC | Increased OS/DFS | [124] | |
| pre-miR-27a | rs895819 A > G | NSCLC | Poor treatment response and reduced OS | [125] | |
| miR-5197 a | rs2042253 T > C | NSCLC | Increased OS | [126] | |
| DROSHA | rs6886834 G > A | NSCLC | Reduced RFS | [109] | |
| XPO5 | rs11077 A > C | NSCLC | Increased time to recurrence | [108] | |
| SCLC | Reduced OS | [127] | |||
| pri-miR-26a-1 | rs7372209 C > T | CRC | Reduced time to progression | [128] | |
| pri-miR-100 | rs1834306 T > C | CRC | Increased time to progression | [128] | |
| miR-219-1 | rs213210 T > C | CRC | Increased RFS | [129] | |
| CRC | Increased OS/RFS | [130] | |||
| miR-608 | rs4919510 C > G | CRC | Decreased RFS | [129] | |
| CRC | Increased EFS | [130] | |||
| KIF3C | rs6728684 T > G | PC | Reduced PFS | [124] | |
| IFI30 | rs1045747 T > C | PC | Reduced PFS | [121] | |
| DDX20 | rs197412 C > T | BC | Decreased risk of recurrence | [131] | |
| DGCR8 | rs2073778 G > T | BC | Increased risk of progression | [131] | |
| XPO5 | rs11077 A > C | MM | Increased OS | [119] | |
| HL | Increased OS/DFS for heterozygotes | [118] | |||
| HCC | Increased OS | [132] | |||
| RNASEN | rs17408716 A > G | OC | Better treatment response and increased OS | [116] |
a MiRNAs that are not listed as bona fide miRNAs in MirGeneDB [5]. NSCLC: non-small cell lung cancer; SCLC: small cell lung cancer; LC: lung cancer; CRC: colorectal cancer; OC: Ovarian cancer; HCC: hepatocellular carcinoma; HL: Hodgkin lymphoma; MM: multiple myeloma; BC: bladder cancer; PC: prostate cancer.